Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer

Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis... Purpose of ReviewThis review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).Recent FindingsThe MPN natural history is driven by uncontrolled clonal myeloproliferation sustained by acquired somatic mutations in driver (JAK2, CALR, and MPL) and non-driver genes, involving epigenetic (e.g., TET2, DNMT3A) regulators, chromatin regulator genes (e.g., ASXL1, EZH2), and splicing machinery genes (e.g., SF3B1). The genomic alterations and additional thrombosis acquired risk factors are determinants for CVE. There is evidence that clonal hematopoiesis can elicit a chronic and systemic inflammation status that acts as driving force for the development of thrombosis, MPN evolution, and second cancer (SC). This notion may explain the mechanism that links arterial thrombosis in MPN patients and subsequent solid tumors. In the last decade, clonal hematopoiesis of indeterminate potential (CHIP) has been detected in the general population particularly in the elderly and initially found in myocardial infarction and stroke, rising the hypothesis that the inflammatory status CHIP-associated could confer predisposition to both cardiovascular diseases and cancer.SummaryIn summary, clonal hematopoiesis in MPN and CHIP confer a predisposition to cardiovascular events and cancer through chronic and systemic inflammation. This acquisition could open new avenues for antithrombotic therapy both in MPNs and in general population by targeting both clonal hematopoiesis and inflammation. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Hematologic Malignancy Reports Springer Journals

Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer

Download PDF
8 pages

Loading next page...
 
/lp/springer-journals/clonal-hematopoiesis-in-myeloproliferative-neoplasms-confers-a-OMlrRz2H3h
Publisher
Springer Journals
Copyright
Copyright © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
ISSN
1558-8211
eISSN
1558-822X
DOI
10.1007/s11899-023-00697-5
Publisher site
See Article on Publisher Site

Abstract

Purpose of ReviewThis review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).Recent FindingsThe MPN natural history is driven by uncontrolled clonal myeloproliferation sustained by acquired somatic mutations in driver (JAK2, CALR, and MPL) and non-driver genes, involving epigenetic (e.g., TET2, DNMT3A) regulators, chromatin regulator genes (e.g., ASXL1, EZH2), and splicing machinery genes (e.g., SF3B1). The genomic alterations and additional thrombosis acquired risk factors are determinants for CVE. There is evidence that clonal hematopoiesis can elicit a chronic and systemic inflammation status that acts as driving force for the development of thrombosis, MPN evolution, and second cancer (SC). This notion may explain the mechanism that links arterial thrombosis in MPN patients and subsequent solid tumors. In the last decade, clonal hematopoiesis of indeterminate potential (CHIP) has been detected in the general population particularly in the elderly and initially found in myocardial infarction and stroke, rising the hypothesis that the inflammatory status CHIP-associated could confer predisposition to both cardiovascular diseases and cancer.SummaryIn summary, clonal hematopoiesis in MPN and CHIP confer a predisposition to cardiovascular events and cancer through chronic and systemic inflammation. This acquisition could open new avenues for antithrombotic therapy both in MPNs and in general population by targeting both clonal hematopoiesis and inflammation.

Journal

Current Hematologic Malignancy Reports – Springer Journals

Published: Aug 1, 2023

Keywords: Myeloproliferative neoplasms; Thrombosis; Clonal hematopoiesis of indeterminate potential; Cancer; Inflammation; Disease progression

References

  • Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2
    Nangalia, J; Massie, CE; Baxter, EJ; Nice, FL; Gundem, G; Wedge, DC
  • Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
    Lundberg, P; Karow, A; Nienhold, R; Looser, R; Hao-Shen, H; Nissen, I
  • Classification and personalized prognosis in myeloproliferative neoplasms
    Grinfeld, J; Nangalia, J; Baxter, EJ; Wedge, DC; Angelopoulos, N; Cantrill, R
  • Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment
    Barbui, T; Carobbio, A; De Stefano, V
  • The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms
    Hasselbalch, HC; Elvers, M; Schafer, AI
  • Essential thrombocythemia
    Tefferi, A; Pardanani, A
  • Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study
    Hultcrantz, M; Bjorkholm, M; Dickman, PW; Landgren, O; Derolf, AR; Kristinsson, SY
  • Efficacy and safety of low-dose aspirin in polycythemia vera
    Landolfi, R; Marchioli, R; Kutti, J; Gisslinger, H; Tognoni, G; Patrono, C
  • In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology
    Barbui, T; Carobbio, A; Rumi, E; Finazzi, G; Gisslinger, H; Rodeghiero, F
  • Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
    Marchioli, R; Finazzi, G; Landolfi, R; Kutti, J; Gisslinger, H; Patrono, C
  • Cardiovascular events and intensity of treatment in polycythemia vera
    Marchioli, R; Finazzi, G; Specchia, G; Cacciola, R; Cavazzina, R; Cilloni, D
  • Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
    Tefferi, A; Rumi, E; Finazzi, G; Gisslinger, H; Vannucchi, AM; Rodeghiero, F
  • Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
    Carobbio, A; Thiele, J; Passamonti, F; Rumi, E; Ruggeri, M; Rodeghiero, F
  • Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
    Barbui, T; Finazzi, G; Carobbio, A; Thiele, J; Passamonti, F; Rumi, E
  • Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
    Barbui, T; Vannucchi, AM; Buxhofer-Ausch, V; De Stefano, V; Betti, S; Rambaldi, A
  • The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
    Barbui, T; Thiele, J; Gisslinger, H; Kvasnicka, HM; Vannucchi, AM; Guglielmelli, P
  • International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data
    Arber, DA; Orazi, A; Hasserjian, RP; Borowitz, MJ; Calvo, KR; Kvasnicka, HM
  • Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study
    Barbui, T; Thiele, J; Passamonti, F; Rumi, E; Boveri, E; Ruggeri, M
  • Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia
    Finazzi, G; Carobbio, A; Guglielmelli, P; Cavalloni, C; Salmoiraghi, S; Vannucchi, AM
  • Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis
    Guglielmelli, P; Carobbio, A; Rumi, E; De Stefano, V; Mannelli, L; Mannelli, F
  • Thrombosis in primary myelofibrosis: incidence and risk factors
    Barbui, T; Carobbio, A; Cervantes, F; Vannucchi, AM; Guglielmelli, P; Antonioli, E
  • Association between myelofibrosis and thromboembolism: a population-based retrospective cohort study
    Saliba, W; Mishchenko, E; Cohen, S; Rennert, G; Preis, M
  • Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients
    Mora, B; Guglielmelli, P; Kuykendall, A; Rumi, E; Maffioli, M; Palandri, F
  • Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
    Barbui, T; Ghirardi, A; Carobbio, A; Masciulli, A; Carioli, G; Rambaldi, A
  • Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases
    De Stefano, V; Rossi, E; Carobbio, A; Ghirardi, A; Betti, S; Finazzi, G
  • Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet
    Barbui, T; Barosi, G; Birgegard, G; Cervantes, F; Finazzi, G; Griesshammer, M
  • Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
    Barbui, T; Tefferi, A; Vannucchi, AM; Passamonti, F; Silver, RT; Hoffman, R
  • Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
    Gerds, AT; Gotlib, J; Ali, H; Bose, P; Dunbar, A; Elshoury, A
  • Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
    Gisslinger, H; Klade, C; Georgiev, P; Krochmalczyk, D; Gercheva-Kyuchukova, L; Egyed, M
  • A randomized phase 3 trial of interferon-alpha vs hydroxyurea in polycythemia vera and essential thrombocythemia
    Mascarenhas, J; Kosiorek, HE; Prchal, JT; Rambaldi, A; Berenzon, D; Yacoub, A
  • Benefits and pitfalls of pegylated interferon-alpha2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study
    Ianotto, JC; Chauveau, A; Boyer-Perrard, F; Gyan, E; Laribi, K; Cony-Makhoul, P
  • Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis
    Silver, RT; Kiladjian, JJ; Hasselbalch, HC
  • Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
    Yacoub, A; Mascarenhas, J; Kosiorek, H; Prchal, JT; Berenzon, D; Baer, MR
  • Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations
    Marchetti, M; Vannucchi, AM; Griesshammer, M; Harrison, C; Koschmieder, S; Gisslinger, H
  • Ruxolitinib versus best available therapy for PV intolerant or resistant to hydroxycarbamide in a randomized trial
    Harrison, C; Nangalia, J; Boucher, RH; Jackson, A; Yap, C; O’Sullivan, J
  • Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial
    Barbui, T; Vannucchi, AM; De Stefano, V; Masciulli, A; Carobbio, A; Ferrari, A
  • Arterial thromboembolic events preceding the diagnosis of cancer in older persons
    Navi, BB; Reiner, AS; Kamel, H; Iadecola, C; Okin, PM; Tagawa, ST
  • Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study
    De Stefano, V; Ghirardi, A; Masciulli, A; Carobbio, A; Palandri, F; Vianelli, N
  • Arterial thrombosis and second cancer in MPNs
    Arcasoy, MO
  • Second cancers in MPN: Survival analysis from an international study
    Marchetti, M; Ghirardi, A; Masciulli, A; Carobbio, A; Palandri, F; Vianelli, N
  • The incidence of cancer-associated thrombosis is increasing over time
    Mahajan, A; Brunson, A; Adesina, O; Keegan, THM; Wun, T
  • Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?
    Langley, RE; Burdett, S; Tierney, JF; Cafferty, F; Parmar, MK; Venning, G
  • Age-related clonal hematopoiesis associated with adverse outcomes
    Jaiswal, S; Fontanillas, P; Flannick, J; Manning, A; Grauman, PV; Mar, BG
  • Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
    Genovese, G; Kahler, AK; Handsaker, RE; Lindberg, J; Rose, SA; Bakhoum, SF
  • Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease
    Marnell, CS; Bick, A; Natarajan, P
  • Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease
    Jaiswal, S; Natarajan, P; Silver, AJ; Gibson, CJ; Bick, AG; Shvartz, E
  • Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3
    Barbui, T; Carobbio, A; Finazzi, G; Vannucchi, AM; Barosi, G; Antonioli, E
  • Leukocytosis and thrombosis in polycythemia vera: can clinical trials settle the debate?
    Barbui, T; Carobbio, A; Ferrari, A
  • Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis
    Carobbio, A; Ferrari, A; Masciulli, A; Ghirardi, A; Barosi, G; Barbui, T
  • MPNs as inflammatory diseases: the evidence, consequences, and perspectives
    Hasselbalch, HC; Bjorn, ME
  • Specialized regulatory T cells control venous blood clot resolution through SPARC
    Shahneh, F; Grill, A; Klein, M; Frauhammer, F; Bopp, T; Schafer, K
  • Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera
    Carobbio, A; Vannucchi, AM; De Stefano, V; Masciulli, A; Guglielmelli, P; Loscocco, GG
  • Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia
    Farrukh, F; Guglielmelli, P; Loscocco, GG; Pardanani, A; Hanson, CA; De Stefano, V
  • Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes
    Coombs, CC; Zehir, A; Devlin, SM; Kishtagari, A; Syed, A; Jonsson, P
  • Cancer incidence and mortality according to pre-existing heart failure in a community-based cohort
    Bertero, E; Robusto, F; Rulli, E; D’Ettorre, A; Bisceglia, L; Staszewsky, L
  • Could clonal hematopoiesis explain the link between increased cancer mortality incidence in heart failure?
    Brahmbhatt, DH; Scolari, FL; Billia, F
  • Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?
    Hasselbalch, HC; Riley, CH
  • Statin treatment, oxidative stress and inflammation in a Danish population
    Sorensen, AL; Hasselbalch, HC; Nielsen, CH; Poulsen, HE; Ellervik, C
  • Colchicine in patients with chronic coronary disease
    Nidorf, SM; Fiolet, ATL; Mosterd, A; Eikelboom, JW; Schut, A; Opstal, TSJ
  • Safety and efficacy of colchicine in patients with stable CAD and ACS: a systematic review and meta-analysis
    Ullah, W; Haq, S; Zahid, S; Gowda, SN; Ottman, P; Saleem, S
  • Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
    Ridker, PM; Libby, P; MacFadyen, JG; Thuren, T; Ballantyne, C; Fonseca, F
  • Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm
    Pedersen, KM; Colak, Y; Hasselbalch, HC; Bojesen, SE; Nordestgaard, BG